MA
MRKR icon

MYDA Advisors’s Marker Therapeutics MRKR Stock Holding History

MYDA Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-6,800
Closed -$539K – 137
2019
Q2 		$539K Sell
6,800
-1,497
-18% -$88.9K 0.18% 70
2019
Q1 		$548K Buy
+8,297
New +$484K 0.28% 68
2018
Q4 		– Sell
-4,685
Closed -$424K – 109
2018
Q3 		$424K Buy
4,685
+705
+18% +$60.5K 0.23% 93
2018
Q2 		$375K Buy
+3,980
New +$203K 0.16% 103

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

MYDA Advisors's MRKR Position: Q3 2019 in Review

MYDA Advisors sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 6,800 shares — an estimated $539K sold.

MYDA Advisors first reported a position in MRKR in Q2 2018 and held it in 4 quarters. The position peaked at $548K in Q1 2019. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

  • MYDA Advisors reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
  • MYDA Advisors sold 6,800 Marker Therapeutics shares in Q3 2019, an estimated $539K.
  • MYDA Advisors first reported a position in Marker Therapeutics in Q2 2018 and held it in 4 quarters.
  • MYDA Advisors's Marker Therapeutics position peaked at $548K in Q1 2019.
  • 73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on MYDA Advisors's 13F filing for Q3 2019, filed 13 Nov 2019.